Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.44 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | IDH1 | O75874 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.42 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.42 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6109806 | 0.85 | SLC6A2 (0.52) | GLANR3C1NR3C2CYP19A1CYP11B1 | |
| SCHEMBL13788312 | 0.84 | GLA (0.46) | GLANR3C1NR3C2CYP19A1CYP11B1 | |
| SCHEMBL15332987 | 0.82 | GLA (0.49) | GLANR3C1NR3C2CYP19A1CYP11B1 | |
| SCHEMBL23964496 | 0.82 | ATM (0.37) | GLANR3C1NR3C2CYP19A1CYP11B1 | |
| SCHEMBL11910303 | 0.81 | GLA (0.47) | GLACYP19A1CYP11B1CYP11B2HRH3 | |
| SCHEMBL23621741 | 0.81 | KIF11 (0.47) | CYP11B2HRH3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL5228917 | 0.81 | L3MBTL1 (0.48) | GLANR3C1NR3C2CYP19A1CYP11B1 | |
| SCHEMBL17103543 | 0.81 | ESR1 (0.36) | GLANR3C1NR3C2HRH3IDH1 | |
| SCHEMBL12070643 | 0.80 | GLA (0.43) | GLANR3C1NR3C2CYP19A1CYP11B1 | |
| SCHEMBL6110413 | 0.80 | LMNA (0.47) | GLAIDH1FOLH1MRGPRX4MEP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2024-07-18 | — | — | US | disclosed |
| US-20240074309-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-02-29 | — | — | US | disclosed |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | GENZYME CORPORATION | 2023-11-02 | — | — | US | disclosed |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | Madera Therapeutics, LLC | 2023-10-26 | — | — | US | disclosed |
| US-20230265063-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-24 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | AGILENT TECHNOLOGIES, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-01-05 | — | — | US | disclosed |
| EP-4019520-A1 | HETEROCYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING HETEROCYCLIC COMPOUND, AND ELECTRONIC APPARATUS INCLUDING ORGANIC LIGHT-EMITTING DEVICE | Samsung Electronics Co., Ltd. (KR) | 2022-06-29 | — | — | EP | disclosed |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | KARO BIO AB (SE) | 2008-01-31 | — | — | US | disclosed |
| US-7319163-B2 | Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders | KARO BIO AB (SE) | 2008-01-15 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | GLAXO GROUP LIMITED | 2007-10-25 | — | — | US | disclosed |
| WO-2007091046-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
| WO-2007083207-A1 | SUBSTITUTED IMIDAZOLES AND THEIR USE AS PESTICIDES | PFIZER LIMITED (GB) | 2007-07-26 | — | — | WO | disclosed |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | PFIZER INC. (US) | 2007-07-19 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249664-A1 | Muscarinic Acetylcholine Receptor Antagonists | CHRM3, CHRNG, CHRM2 | GLA 2458/4885NR3C1 899/4885NR3C2 755/4885 |
| US-20080027096-A1 | Novel Pharmaceutical Compositions | AR, NR5A1, CYP17A1 | GLA 1597/4885NR3C1 40/4885NR3C2 7/4885 |
| US-20230265063-A1 | ORGANIC COMPOUND, AND ELECTRONIC ELEMENT AND ELECTRONIC DEVICE USING SAME | PIEZO1, OR10J3, OR51E2 | GLA 3046/4885NR3C1 2355/4885NR3C2 1481/4885 |
| US-20230348450-A1 | CARBOXYLIC ACID-CONTAINING COMPOUNDS AS MODULATORS OF BIS-PHOSPHOGLYCERATE MUTASE FOR THE TREATMENT OF SICKLE CELL DISEASE | BPGM, PGAM1, PGM2 | GLA 375/4885NR3C1 4502/4885NR3C2 4595/4885 |
| US-20240074309-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | PIEZO1, TMEM109, USE1 | GLA 3819/4885NR3C1 3605/4885NR3C2 3625/4885 |
| US-11731943-B2 | Therapeutic compounds, compositions and methods of use thereof | JAK2, JAK1, JAK3 | GLA 3636/4885NR3C1 898/4885NR3C2 469/4885 |
| US-20070167506-A1 | SUBSTITUTED IMIDAZOLES | ABL1, TYR, CYP3A4 | GLA 2421/4885NR3C1 4070/4885NR3C2 2205/4885 |
| US-11584773-B2 | Phosphorous protecting groups and methods of preparation and use thereof | POLN, POLRMT, NUDT21 | GLA 2235/4885NR3C1 4355/4885NR3C2 4503/4885 |
| US-20230339947-A1 | USE OF CASEINOLYTIC PROTEASE P FUNCTION AS A BIOMARKER OF DRUG RESPONSE TO IMIPRIDONE-LIKE AGENTS | CLPP, PRCP, PREP | GLA 371/4885NR3C1 3521/4885NR3C2 2475/4885 |
| US-20230002369-A1 | Bcl-2 INHIBITORS | BCL2, BCL2L1, BCL2L2 | GLA 2497/4885NR3C1 2691/4885NR3C2 2548/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | GLA 810/4885NR3C1 75/4885NR3C2 131/4885 |
| US-20240244961-A1 | ORGANIC COMPOUND, ELECTRONIC ELEMENT AND ELECTRONIC APPARATUS | AOX1, AOC2, OSTC | GLA 3184/4885NR3C1 1496/4885NR3C2 790/4885 |
| US-20070185155-A1 | Muscarinic acetylcholine receptor antagonists | CHRM3, CHRNG, CHRM2 | GLA 2458/4885NR3C1 899/4885NR3C2 755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.